Q1 2025 Harvard Bioscience Inc Earnings Call Transcript
Key Points
- Harvard Bioscience Inc (HBIO) has introduced new products, including the SoHo family of implanted telemetry devices and the VivaMARS system, which are expected to drive future growth.
- The company reported improved cash flow from operations, increasing to $3 million in Q1 2025 from $1.4 million in Q1 2024, driven by better working capital management.
- Harvard Bioscience Inc (HBIO) is making progress in refinancing its debt facility, with multiple providers showing interest.
- The company is seeing strong interest in its MeshMEA organoid platform, particularly from academic and industrial customers, driven by new policy changes encouraging alternative methods in drug development.
- Harvard Bioscience Inc (HBIO) has achieved approximately $1 million in consumable revenue from its first large bioproduction customer, indicating traction in this segment.
- Revenue for Q1 2025 was $21.8 million, down from $24.5 million in Q1 2024, reflecting a decline in sales across several regions.
- The company recorded a significant non-cash goodwill impairment charge of $48 million, impacting its operating expenses and financial results.
- Gross margin decreased to 56% in Q1 2025 from 60.3% in Q1 2024, affected by lower absorption of fixed manufacturing overhead and changes in accounting methods.
- Harvard Bioscience Inc (HBIO) faces uncertainty in NIH and academic research funding, which could impact future revenue and growth.
- The company anticipates a challenging Q2 2025, with expected revenue in the range of $18 million to $20 million, partly due to the impact of China tariffs and softening revenue in the region.
Good day and welcome to the first quarter 2025 Harvard Bioscience Inc earnings conference call. (Operator Instructions)Please note this event is being recorded. I would now like to turn the conference over to Kathryn Flynn, the Corporate Controller. Please go ahead.
Thank you, [Betsy], and good morning, everyone. Thank you for joining the Harvard Bioscience first quarter 2025 earnings conference call. Leading the call today will be Jim Green, President and Chief Executive Officer, and Mark Frost, the incoming Interim Chief Financial Officer.
In conjunction with today's recorded call, we have provided a presentation that will be referenced during our remarks that is posted to the investors section of our website at investor.harvardbioscience.com.
Please note that statements made in today's discussion that are not historical facts, including statements or expectations or future events or future financial performance are forward-looking statements and are made pursuant to the safe
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
